Amylyx Pharmaceuticals Announces New Insights from Avexitide Clinical Trials for Post-Bariatric Hypoglycemia at ENDO 2025

Reuters
08 Jul
<a href="https://laohu8.com/S/AMLX">Amylyx Pharmaceuticals</a> Announces New Insights from Avexitide Clinical Trials for Post-Bariatric Hypoglycemia at ENDO 2025

Amylyx Pharmaceuticals Inc. has announced plans to host an investor event at the Endocrine Society's annual meeting (ENDO 2025) to discuss post-bariatric hypoglycemia $(PBH)$ and avexitide, a potential first-in-class GLP-1 receptor antagonist. The event will take place on July 13, 2025, both in-person in San Francisco and virtually. The presentation will cover the current burden of PBH and provide background information on avexitide, which has received FDA breakthrough therapy designation. Additionally, the event will feature new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide in PBH, with data focusing on composite rates of Level 2 and 3 hypoglycemic events, as well as pharmacokinetic and pharmacodynamic data demonstrating the continuous pharmacologic activity of the 90 mg once daily dose for 24 hours. The results of these studies will be presented during ENDO 2025. A live webcast of the presentation and Q&A will be available on Amylyx's website, with a replay accessible for 90 days following the event.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250708428715) on July 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10